申请人:Mitsubishi Yuka Pharmaceutical Co., Ltd.
公开号:US04128646A1
公开(公告)日:1978-12-05
Substituted pyrimido[5,6-b]quinoxaline-4(3H)-one-2-carboxylic acid compounds each represented by the formula ##STR1## wherein: R designates a member selected from the group consisting of hydrogen, alkyl groups having 1 to 4 carbon atoms, benzyl group, and phenyl group; and each of R.sup.1, R.sup.2, R.sup.3, and R.sup.4 independently designates a member selected from the group consisting of hydrogen, alkyl group having 1 to 4 carbon atoms, alkoxy groups having 1 to 4 carbon atoms, halogens, benzyloxy group, hydroxyl group, alkylthio groups having 1 to 4 carbon atoms, and alkylenedioxy groups having 1 to 4 carbon atoms and formed by the bonding of two of R.sup.1, R.sup.2, R.sup.3, and R.sup.4, or pharmacologically acceptable salts of said compounds.
化合物为取代的嘧啶并[5,6-b]喹啉-4(3H)-酮-2-羧酸化合物,其表示为以下式子:##STR1## 其中:R代表从氢,具有1至4个碳原子的烷基,苄基和苯基中选择的成员;R.sup.1,R.sup.2,R.sup.3和R.sup.4中的每一个独立地表示从氢,具有1至4个碳原子的烷基,具有1至4个碳原子的烷氧基,卤素,苄氧基,羟基,具有1至4个碳原子的烷基硫基和由R.sup.1,R.sup.2,R.sup.3和R.sup.4中的两个成员结合形成的具有1至4个碳原子的烷基二氧基基团中选择的成员,或其药理学上可接受的盐。